Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Bristol-Myers Squibb
Sanofi
Verastem, Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Zai Lab (Hong Kong), Ltd.